Electric shocks boost drug to shrink blood vessel tangles

NCT ID NCT07579962

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new treatment called bleomycin electrosclerotherapy (BEST) for low-flow vascular malformations—abnormal clusters of blood or lymph vessels. The approach combines an injected drug (bleomycin) with brief electrical pulses to make the drug work better. Researchers will enroll 140 adults whose malformations didn't respond well to prior treatments, and they'll measure changes in lesion size using MRI at 3 and 12 months after treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Bleomycin (a chemotherapy drug) injected into the malformation, followed by electrical pulses to boost its effect
What this could lead to
If it works, this could offer a more effective, less invasive treatment option for people with hard-to-treat vascular malformations, potentially reducing the need for surgery.
What could go wrong
This is a phase 2 trial with only 140 participants, so results are preliminary. The treatment involves bleomycin, which can have side effects like skin changes or lung issues, and the electrical pulses may cause discomfort or local reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for VASCULAR MALFORMATIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.